Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 17/20 | 0.66 |
| ▸ | DHFR | P00374 | 3/20 | 0.66 |
| ▸ | FOLR1 | P15328 | 2/20 | 0.66 |
| ▸ | SLC19A1 | P41440 | 2/20 | 0.66 |
| ▸ | SLC46A1 | Q96NT5 | 2/20 | 0.66 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.66 |
| ▸ | GART | P22102 | 1/20 | 0.66 |
| ▸ | ATIC | P31939 | 1/20 | 0.66 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.66 |
| ▸ | FRK | P42685 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12598435 | 1.00 | TYMS (0.66) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL12314789 | 0.91 | TYMS (0.66) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL13181213 | 0.90 | TYMS (0.78) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL18659339 | 0.90 | TYMS (0.78) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL2610602 | 0.90 | TYMS (0.67) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL14665910 | 0.89 | GART (0.81) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL14523040 | 0.87 | TYMS (0.63) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL13448780 | 0.86 | TYMS (0.67) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL10306802 | 0.85 | DHFR (0.54) | TYMSDHFRFOLR1SLC19A1SLC46A1 | |
| SCHEMBL12314803 | 0.84 | TYMS (0.60) | TYMSDHFRFOLR1SLC19A1SLC46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245349-A1 | Process for the production of a pemetrexed salt | SCINOPHARM TAIWAN, LTD. | 2012-09-27 | — | — | US | disclosed |
| US-20110301169-A1 | Therapies for Treating Cancer Using Combinations of COX-2 Inhibitors and Antimetabolites | TRAGARA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | MERCK SHARP & DOHME CORP. | 2011-04-21 | — | — | US | disclosed |
| US-20100113392-A1 | METHODS OF USING SAHA AND BORTEZOMIB FOR TREATING MULTIPLE MYELOMA | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
| WO-2010030598-A2 | PHARMACEUTICAL FORMULATIONS COMPRISING PEMETREXED | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245349-A1 | Process for the production of a pemetrexed salt | DHFR, TYMS, MTHFD1 | TYMS 2/4885DHFR 1/4885FOLR1 21/4885 |
| US-20100113392-A1 | METHODS OF USING SAHA AND BORTEZOMIB FOR TREATING MULTIPLE MYELOMA | HDAC5, HDAC4, HDAC6 | TYMS 4554/4885DHFR 3935/4885FOLR1 4485/4885 |
| US-20110301169-A1 | Therapies for Treating Cancer Using Combinations of COX-2 Inhibitors and Antimetabolites | PTGS2, PTGES2, PTGER2 | TYMS 539/4885DHFR 37/4885FOLR1 360/4885 |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | IGF1R, IGFBP1, IGFBP2 | TYMS 1587/4885DHFR 2522/4885FOLR1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.